Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma

Moonsik Kim, Jihwan Yoo, Jong Hee Chang, Se Hoon Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: The methylation status of the O6methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.

Original languageEnglish
Pages (from-to)335-341
Number of pages7
JournalAnticancer research
Issue number1
Publication statusPublished - 2022 Jan

Bibliographical note

Funding Information:
Se Hoon Kim was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (Grant No. 2016M3C7A1913844). The funding source had no role in the design, practice, or analysis of this study.

Publisher Copyright:
© 2022 International Institute of Anticancer Research. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Association of MGMT Gene Promoter Methylation with Clinicopathological Parameters in Patients with Wild-type IDH Glioblastoma'. Together they form a unique fingerprint.

Cite this